Summit Therapeutics (NASDAQ:SMMT) traded higher for the fifth straight session on Thursday as investors continued to cheer ...

BeiGene stock has formed an early-stage base with a buy point of 287.88 ahead of its first-quarter results on May 7.

Shares of lung cancer biotech Summit Therapeutics (NASDAQ: SMMT) rocketed 14.7% on Wednesday as of 1:45 p.m. ET. Summit ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...

Analysts at BMO Capital Markets expect Summit and Akeso's HARMONi-6 readout to put some pressure on Merck and its blockbuster ...

Summit Therapeutics and Akeso said their PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of lung cancer.

Dr. Mekan brings a combined 18 years of experience in hematology and oncology across academic research, clinical practice and biopharmaceutical industry development, and I am excited to welcome her to ...

The firms will use nFerence's Agentic AI platform to analyze real-world treatment patterns in 700 patients' charts and inform personalized care.

PRNewswire/ -- nference, a company dedicated to transforming healthcare by making biomedical data computable, today announced a collaboration with BeiGene, Ltd, a global oncology company that intends ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on ...

In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.